In a move that will delight Novo Nordisk and Eli Lilly, the FDA has sent warning letters to 30 telehealth companies, accusing them of illegally marketing compounded GLP-1 agonist formulations. The ...

Discover what Compound crypto is used for, including lending, borrowing, onchain liquidity, and how Compound III manages rates, collateral, and liquidation risk ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Compounded GLP-1 medications help fill a necessary gap, but can have significant safety issues. Compounded GLP-1 medications ...

The agency’s 2023 decision to place 19 peptides on the “unsafe” list was supported by numerous documented safety concerns, ...

Weight-loss company Noom has acquired 503A pharmacy Tailor Made Compounding, which Noom said will allow it to expand its behavior change programs and move beyond weight health. Tailor Made provides ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

WASHINGTON, March 12 (Reuters) - Compounded weight-loss drugs that contain vitamin B12 and the ‌main ingredient in Eli Lilly's (LLY.N), opens new tab Zepbound could present health risks to consumers ...

Testing identified significant impurity formation when tirzepatide is compounded with B12 variants, suggesting chemical incompatibility that is not evaluated under FDA review pathways. Uncertainty ...

DENVER — Colorado state lawmakers are debating regulations about compounded GLP-1 medications. Senate Bill 26-066 is designed to regulate the ingredients in compounded weight loss medications. “We ...

The Food and Drug Administration’s crackdown on cheaper, independently produced versions of popular weight-loss and diabetes medications stoked anger and pushback from users, sellers and the Alliance ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting ...